Loading organizations...
Mobilion Systems is a technology company.
Mobilion Systems develops the MOBIE platform, an advanced analytical instrument utilizing next-generation separation science to characterize complex molecules with enhanced depth, accuracy, and efficiency. Employing Structures for Lossless Ion Manipulations (SLIM) technology and High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS), the platform delivers superior resolution, accelerated analysis, and consistent reproducibility, enabling the detection of molecules previously unseen by other methods.
The company was founded in 2015, arising from the insight that existing analytical instruments struggled with the identification and precise analysis of challenging molecules. While specific founder details are not immediately available, CEO Melissa Sherman has been a pivotal leader in guiding the technology from initial concept to the launch of the MOBIE product. This foundational challenge sparked the development of a system designed to push the boundaries of separation science.
Researchers across biomarker research and diagnostics, cell and gene therapy, food and environmental analysis, and therapeutic characterization rely on Mobilion Systems' technology. The company's vision is to empower pharmaceutical, biopharmaceutical, and academic researchers with unprecedented insights, driving the development of new diagnostics, effective therapeutics, and enhanced quality assurance, ultimately "revealing what others leave unseen."
Mobilion Systems has raised $110.4M across 3 funding rounds.
Mobilion Systems has raised $110.4M in total across 3 funding rounds.
Mobilion Systems is a biotechnology and life sciences technology company that develops advanced analytical instruments for molecular separation and identification, primarily serving pharmaceutical, biopharmaceutical, environmental, and food industries. Their flagship product, the MOBIE® platform, uses high-resolution ion mobility mass spectrometry (HRIM-MS) to enable faster, more sensitive, and highly reproducible detection of complex molecules such as proteins, peptides, metabolites, and lipids. This technology supports earlier disease detection, improved biomarker discovery, and accelerated drug development, addressing critical challenges in metabolic disease research and therapeutic characterization. Mobilion has demonstrated strong growth with $17.5 million in revenue and over $110 million in funding as of 2025, expanding its global presence including recent European market development[1][2][4][5].
Founded in 2015 and headquartered in Chadds Ford, Pennsylvania, Mobilion Systems was established to pioneer next-generation separation science through its proprietary SLIM (Structures for Lossless Ion Manipulation) technology. The founding team leveraged expertise in analytical chemistry and mass spectrometry to address limitations in existing molecular analysis tools, focusing on delivering unprecedented resolution and speed. Early traction came from collaborations with academic institutions and biopharma companies, validating the platform’s ability to detect molecules previously unseen by conventional instruments. This foundation enabled Mobilion to scale its commercial operations and broaden its impact across multiple sectors[1][2].
Mobilion Systems is riding the wave of increasing demand for multi-omics and high-resolution molecular analysis technologies that complement genomics. The timing is critical as precision medicine, biomarker discovery, and biotherapeutic development require more detailed molecular characterization to improve diagnostics and treatment outcomes. Market forces such as rising healthcare costs, the need for earlier disease detection, and regulatory pressures for safer therapeutics favor Mobilion’s advanced analytical solutions. By enabling researchers to detect low-abundance molecules and process large sample volumes rapidly, Mobilion influences the broader ecosystem by accelerating scientific discovery and reducing time-to-market for new drugs and diagnostics[2][4][5].
Mobilion Systems is well-positioned to expand its influence in the biotech and pharmaceutical sectors by continuing to innovate its HRIM-MS platform and scaling global sales and support. Future trends shaping its journey include the growing integration of multi-omics data in clinical research, increasing demand for personalized medicine, and the expansion of environmental and food safety testing. As the company deepens collaborations and enhances its technology, it may evolve from a niche instrument provider to a critical enabler of next-generation diagnostics and therapeutics, further transforming how diseases are understood and treated worldwide[2][4].
Mobilion Systems has raised $110.4M in total across 3 funding rounds.
Mobilion Systems's investors include D1 Capital Partners, Agilent Technologies, Cultivation Capital, Hostplus, aMoon Fund, iSelect Fund.
Mobilion Systems has raised $110.4M across 3 funding rounds. Most recently, it raised $60.0M Series C in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 14, 2021 | $60.0M Series C | D1 Capital Partners | Agilent Technologies, Cultivation Capital, Hostplus |
| Aug 1, 2020 | $35.0M Series B | aMoon Fund, Agilent Technologies, Cultivation Capital, Hostplus | |
| Nov 12, 2019 | $15.4M Series A | Agilent Technologies | Cultivation Capital, Hostplus, iSelect Fund |